BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Brentuximab Vedotin readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Brentuximab Vedotin\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05180097-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05180097)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Pembrolizumab and Brentu
 ximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodg
 kin Lymphoma\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05180097
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755804-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT03755804)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Pediatric Classical Hodg
 kin Lymphoma Consortium Study: cHOD17\nEstimated primary completion: 1 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brentuxima
 b-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03755804
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05357794-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05357794)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Th
 erapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients 
 With Mycosis Fungoides\nEstimated primary completion: 30 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05357794
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377566-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT06377566)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: A Study of BV-AVD in Peo
 ple With Bulky Hodgkin Lymphoma\nEstimated primary completion: April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0637
 7566
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03007030-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT03007030)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Brentuximab Vedotin in T
 reating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed 
 by Surgery\nEstimated primary completion: 1 May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03007030
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01896999-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Brentuximab Vedotin: Phase 1/2 readout est. (NCT01896999)
DESCRIPTION:Brentuximab Vedotin\, phase 1/2.\nStudy: Brentuximab Vedotin an
 d Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed 
 or Refractory Hodgkin Lymphoma\nEstimated primary completion: 30 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT018
 96999
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03587844-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT03587844)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Dosing of Brentuximab Vedotin for Mycosis Fungoides\, Sezary Syndrome 
 Patients\nEstimated primary completion: July 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03587844
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745949-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT04745949)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Large B-Cell Lymphoma.\nStudy: 
 PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody T
 herapy\, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy\nEstima
 ted primary completion: 3 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04745949
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561206-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271002
DTEND;VALUE=DATE:20271003
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT04561206)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Brentuximab Vedotin and 
 Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical
  Hodgkin Lymphoma\nEstimated primary completion: 2 October 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04561206
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05404945-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271003
DTEND;VALUE=DATE:20271004
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05404945)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Fitness-adapted\, Pembro
 lizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60
  Years of Age and Above\nEstimated primary completion: 3 October 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05404945
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05922904-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05922904)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: PET Adapted Brentuximab 
 Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine 
 in Classic Hodgkin Lymphoma\nEstimated primary completion: 30 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 22904
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039073-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05039073)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Brentuximab Vedotin and 
 Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphom
 a Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors\nEs
 timated primary completion: 30 November 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05039073
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587687-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT04587687)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Brentuximab Vedotin and 
 Bendamustine for the Treatment of Relapsed or Refractory Follicular Lympho
 ma\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04587687
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03719105-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Brentuximab Vedotin: Phase 1 readout est. (NCT03719105)
DESCRIPTION:Brentuximab Vedotin\, phase 1\, Peripheral T-Cell Lymphoma.\nSt
 udy: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell 
 Leukemia/Lymphoma\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03719105
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01352520-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT01352520)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL)\, Mycosis
  Fungoides (MF)\, and Extensive Lymphomatoid Papulosis (LyP)\nEstimated pr
 imary completion: 31 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT01352520
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06831370-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Brentuximab Vedotin: Phase 4 readout est. (NCT06831370)
DESCRIPTION:Brentuximab Vedotin\, phase 4.\nStudy: A Study of Brentuximab V
 edotin With Doxorubicin\, Vinblastine and Dacarbazine in Adults With Hodgk
 in Lymphoma in India\nEstimated primary completion: 31 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06831370
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05313243-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT05313243)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Pembrolizumab and Brentu
 ximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma\nEstima
 ted primary completion: 30 April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05313243
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07074457-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Brentuximab Vedotin: Phase na readout est. (NCT07074457)
DESCRIPTION:Brentuximab Vedotin\, phase na\, Peripheral T-Cell Lymphoma.\nS
 tudy: Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL P
 atients\nEstimated primary completion: 1 August 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07074457
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258680-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT07258680)
DESCRIPTION:Brentuximab Vedotin\, phase 3\, Peripheral T-Cell Lymphoma.\nSt
 udy: BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimi
 zing First-line Therapy of T-cell Lymphomas\nEstimated primary completion:
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brent
 uximab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07258680
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06925555-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT06925555)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Diffuse Large B-Cell Lymphoma.\
 nStudy: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DL
 BCL-NOS\nEstimated primary completion: 30 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06925555
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07717580-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT07717580)
DESCRIPTION:Brentuximab Vedotin\, phase 2\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax i
 n CD30+ Cutaneous T-cell Lymphoma (CTCL)\nEstimated primary completion: 30
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brent
 uximab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07717580
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07572123-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Brentuximab Vedotin: Phase 2/3 readout est. (NCT07572123)
DESCRIPTION:Brentuximab Vedotin\, phase 2/3.\nStudy: Evaluating the Additio
 n of Maintenance Immunotherapy Compared to the Usual Treatment of Chemothe
 rapy and Autologous Stem Cell Transplant Alone for High-risk Patients With
  Relapsed or Refractory Hodgkin Lymphoma\nEstimated primary completion: 31
  March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brentuxi
 mab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07572123
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013565-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT07013565)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Chemoimmunotherapy for A
 LK+ Relapsed/Refractory ALCL\nEstimated primary completion: 1 July 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT070135
 65
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275216-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20291020
DTEND;VALUE=DATE:20291021
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT07275216)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: Pembrolizumab in Combina
 tion With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patient
 s Ineligible for Standard Treatment\nEstimated primary completion: 20 Octo
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab
 -vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07275216
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563245-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Brentuximab Vedotin: Phase 2/3 readout est. (NCT06563245)
DESCRIPTION:Brentuximab Vedotin\, phase 2/3.\nStudy: Brentuximab Vedotin fo
 r Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment\nEstimate
 d primary completion: 15 November 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/brentuximab-vedotin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06563245
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07002216-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20300715
DTEND;VALUE=DATE:20300716
SUMMARY:Brentuximab Vedotin: Phase 2 readout est. (NCT07002216)
DESCRIPTION:Brentuximab Vedotin\, phase 2.\nStudy: BrECADD Therapy in Stage
  2 B-IV Hodgkin Lymphoma\nEstimated primary completion: 15 July 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07002216
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04685616-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT04685616)
DESCRIPTION:Brentuximab Vedotin\, phase 3.\nStudy: Brentuximab Vedotin in E
 arly Stage Hodgkin Lymphoma\nEstimated primary completion: September 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0468
 5616
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675410-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT05675410)
DESCRIPTION:Brentuximab Vedotin\, phase 3.\nStudy: A Study to Compare Stand
 ard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs\, Brentuxima
 b Vedotin and Nivolumab\nEstimated primary completion: 28 April 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/brentuximab-vedotin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05675410
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178457-2202@assetmemo.bio
DTSTAMP:20261121T005007Z
DTSTART;VALUE=DATE:20321101
DTEND;VALUE=DATE:20321102
SUMMARY:Brentuximab Vedotin: Phase 3 readout est. (NCT07178457)
DESCRIPTION:Brentuximab Vedotin\, phase 3\, Cutaneous T-Cell Lymphoma.\nStu
 dy: Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogen
 eic Hematopoietic Stem Cell Transplant Maintenance\nEstimated primary comp
 letion: 1 November 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/brentuximab-vedotin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07178457
URL:https://assetmemo.bio/drug/brentuximab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
